Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(<i>R</i>)-(–)-Deprenyl]

Yaşar, Sevil; Justinová, Zuzana; Lee, Sun Hee; Roman, Sabine; Goldberg, Steven R.

doi:10.1124/jpet.105.096263

Cited by 14 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study confirmed whether amphetamine effects associated with MAO-B inhibitors, particularly selegiline, exist from two aspects, and the amphetamine effect of selegiline is not higher than the other two drugs. This result supports that a clinical trial of selegiline has not identified any causal adverse events that can be considered amphetamine effects 32 , and studies using squirrel monkeys and rats have reported no amphetamine effects at normal doses of selegiline 14,15 . In summary, we could not confirm a clear amphetamine effect associated with selegiline and other MAO-B inhibitors from these two comparisons.…”

Section: Discussionsupporting

confidence: 81%

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Asano,

Tian,

Hatabu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson’s disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. Although these drugs inhibit MAO-B, there are pharmacological and chemical differences, such as the inhibitory activity, the non-dopaminergic properties in safinamide, and the amphetamine-like structure in selegiline. MAO-B inhibitors may differ in adverse events (AEs). However, differences in actual practical clinics are not fully investigated. A retrospective study was conducted using FAERS, the largest database of spontaneous adverse events. AE signals for MAO-B inhibitors, including selegiline, rasagiline, and safinamide, were detected using the reporting odds ratio method and compared. Hypocomplementemia, hepatic cyst, hepatic function abnormal, liver disorder and cholangitis were detected for selegiline as drug-specific signals. The amphetamine effect was not confirmed for any of the three MAO-B inhibitors. The tyramine reaction was detected as an AE signal only for rasagiline. Moreover, the REM sleep behavior disorder was not detected as an AE signal for safinamide, suggesting that non-dopaminergic effects might be beneficial. Considering the differences in AEs for MAO-B inhibitors will assist with the appropriate PD medication.

show abstract

Section: Discussionsupporting

confidence: 81%

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Asano,

Tian,

Hatabu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Phenylethylamine is an endogenous amine produced physiologically in the brain. [112][113][114] It seems to be able to inhibit the uptake of dopamine 115 and to produce a reinforcement of dopaminergic transmission. 116 It is biosynthesized from the aminoacid phenylalanine by enzymatic decarboxylation as a result of the bacterial enzyme tyrosine decarboxylase 117 (expressed by gastrointestinal flora).…”

Section: Phenylethylaminementioning

confidence: 99%

“…Some studies showed how the inhibi-tion of MAO may increase the effects of phenylethylamine. 115,119 It is known that the levels of dopamine and phenylethylamine increase after the administration of selegiline 115 (a selective inhibitor of MAO-B).…”

Section: Phenylethylaminementioning

confidence: 99%

Amblyopia Treatment Strategies and New Drug Therapies

Pescosolido¹,

Stefanucci²,

Buomprisco³

et al. 2014

J Pediatr Ophthalmol Strabismus

View full text Add to dashboard Cite

Amblyopia is a unilateral or bilateral reduction of visual acuity secondary to abnormal visual experience during early childhood. It is one of the most common causes of vision loss and monocular blindness and is commonly associated with strabismus, anisometropia, and visual deprivation (in particular congenital cataract and ptosis). It is clinically defined as a two-line difference of best-corrected visual acuity between the eyes. The purpose of this study was to understand the neural mechanisms of amblyopia and summarize the current therapeutic strategies. In particular, the authors focused on the concept of brain plasticity and its implication for new treatment strategies for children and adults with amblyopia.

show abstract

“…Selegiline is metabolized to amphetamine derivatives, which recently have been shown to inhibit the neuroprotective actions of both Selegiline and desmethyl selegiline in vivo (Jenner and Langston, 2011). The increase in amphetamine derivatives following Selegiline treatment have in fact recently been a matter of debate as potentially harmful (Yasar et al, 2006). This has, however, not been reported in PD patients.…”

Section: Histological Studymentioning

confidence: 99%

3.146 Modulation of Adult Neurogenesis in the Olfactory Bulb in an Acute Mouse Model of Parkinson's Disease

Chiu¹,

Carlsson²,

Arend³

et al. 2012

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)-(–)-Deprenyl]

Cited by 14 publications

References 39 publications

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Amblyopia Treatment Strategies and New Drug Therapies

3.146 Modulation of Adult Neurogenesis in the Olfactory Bulb in an Acute Mouse Model of Parkinson's Disease

Contact Info

Product

Resources

About